All
FDA Approves Elrexfio for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
August 14th 2023The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.